Scinai Immunotherapeutics Ltd.(SCNI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SCNI Scinai Immunotherapeutics Ltd.

Trading 03-17 15:01:23 EDT

0.7200

+0.0200

+2.86%

High0.7285	Low0.6900	Vol5.33K
Open0.6992	D1 Closing0.7000	Amplitude5.50%
Mkt Cap2.50M	Tradable Cap2.20M	Total Shares3.47M
T/O3.74K	T/O Rate0.17%	Tradable Shares3.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SCNI","market":"US","secType":"STK","nameCN":"Scinai Immunotherapeutics Ltd.","latestPrice":0.72,"timestamp":1773773178476,"preClose":0.7,"halted":0,"volume":5325,"delay":0,"changeRate":0.0285714285714286,"floatShares":3061700,"shares":3468224,"eps":0.263692,"marketStatus":"Trading","change":0.02,"latestTime":"03-17 15:01:23 EDT","open":0.6992,"high":0.7285,"low":0.69,"amount":3739.36836,"amplitude":0.055,"askPrice":0.75,"askSize":500,"bidPrice":0.6826,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.263692,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773777600000},"marketStatusCode":2,"adr":0,"adrRate":4000,"listingDate":1431403200000,"exchange":"NASDAQ","adjPreClose":0.7,"preHourTrading":{"tag":"盘前","latestPrice":0.7342,"preClose":0.7,"latestTime":"09:15 EDT","volume":7,"amount":5.16220012,"timestamp":1773753316751,"change":0.0342,"changeRate":0.048857,"amplitude":0.032571},"postHourTrading":{"tag":"盘后","latestPrice":0.7,"preClose":0.7,"latestTime":"19:34 EDT","volume":6,"amount":4.4288,"timestamp":1773704085461,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.442795},"requestUrl":"/m/hq/s/SCNI","defaultTab":"news","newsList":[{"id":"2616353664","title":"Press Release: Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised EUR12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353664","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616353664?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:20","pubTimestamp":1772461200,"startTime":"0","endTime":"0","summary":"JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. ;, today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under the European Funds for the Modern Economy  SMART Path program.The Company's revised application seeks EUR12 million in non-dilutive, non-repayable funding to support a EUR15 million integrated R&D program for PC111 a fully human monoclonal antibody targeting soluble Fas Ligand  for the treatment of pemphigus vulgaris  and Stevens--Johnson Syndrome/Toxic Epidermal Necrolysis , representing 80% project co-financing. The Company expects a funding decision within approximately three to four months following submission.The Second Amendment aligns the option timeline with the grant evaluation process. Under the amended terms, the deadline for fulfillment of the option conditions extends to August 31, 2026, and the option exercise period extends to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","FENG","SCNI","CDMO","BK4007","BK4139"],"gpt_icon":0},{"id":"2614272346","title":"ADRs Advance; Scinai Immunotherapeutics Ltd. Climbs 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614272346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614272346?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:30","pubTimestamp":1771968600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Tuesday, as the S&P/BNY Mellon index of American depositary receipts gained 1.0% to 265.26.The European index rose 0.3% to 230.14. The Asian index increased 1.8% to 356.82. The Latin American index increased 1.5% to 290.03, while the emerging-markets index gained 2.5% to 606.46.Israel's Scinai Immunotherapeutics Ltd. was the biggest leader during the session, jumping 18% to 86 cents, and China-based The9 Ltd. surged 17% to $5.92. Canaan Inc., which is based in China, rounded out the top three leaders on Tuesday, with shares surging 16% to 50 cents.Yimutian Inc., based in China, posted the largest decline, plummeting 28% to 63 cents, followed by shares of China's Huize Holding Ltd., which plunged 11% to $1.84. Shares of China-based DouYu International Holdings Ltd. tumbled 11% to $4.48.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SCNI","BK4007"],"gpt_icon":0},{"id":"2612519064","title":"Press Release: Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm","url":"https://stock-news.laohu8.com/highlight/detail?id=2612519064","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612519064?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329600,"startTime":"0","endTime":"0","summary":"JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm.The transactions significantly expand Scinai's manufacturing footprint, capabilities, and commercial positioning, strengthening its CDMO platform and creating a differentiated, end-to-end development and manufacturing offering spanning early development directly by Scinai and late-stage clinical and commercial supply by Recipharm. Under the collaboration agreement, development activities and tech transfer will be set up between the companies in a manner designed to facilitate an efficient and frictionless graduation of Scinai clients to Recipharm at the appropriate stage. As a resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO","BK4007","91348","SCNI"],"gpt_icon":0},{"id":"2591682644","title":"This Is Why Scinai Immunotherapeutics Ltd.'s (NASDAQ:SCNI) CEO Compensation Looks Appropriate","url":"https://stock-news.laohu8.com/highlight/detail?id=2591682644","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591682644?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:57","pubTimestamp":1765803472,"startTime":"0","endTime":"0","summary":"Key Insights Scinai Immunotherapeutics to hold its Annual General Meeting on 22nd of December Total pay for CEO Amir...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-scni/scinai-immunotherapeutics/news/this-is-why-scinai-immunotherapeutics-ltds-nasdaqscni-ceo-co","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-scni/scinai-immunotherapeutics/news/this-is-why-scinai-immunotherapeutics-ltds-nasdaqscni-ceo-co","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USJW.SI","TSYW.SI","NVIW.SI","USAW.SI","QLD","NQmain",".IXIC","MNQmain","BK4139","SCNI","BK4007","PSQ","TQQQ","QID","SQQQ"],"gpt_icon":1},{"id":"2588674056","title":"Press Release: Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2588674056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588674056?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:50","pubTimestamp":1764683400,"startTime":"0","endTime":"0","summary":"JERUSALEM, Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its financial results and corporate highlights for the nine months ended September 30, 2025.-- Revenues for the nine months ended September 30, 2025 were $1,049. thousand, compared to $452 thousand for the nine months ended September. 30, 2024. The increase reflects continued expansion of Scinai Bioservices,$1,799 thousand, compared to $4,195 thousand for the nine months ended. employees and facility costs to the R&D business unit.-- Marketing, general and administrative expenses for the nine months ended. September 30, 2025 were $1,929 thousand, compared to $1,767 thousand for. were $607 thousand compared to financial income of $13,374 thousand for. by the financial income from loan conversion recorded in 2024.-- Net loss for the nine months ended Se","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CDMO","SCNI","BK4139"],"gpt_icon":0},{"id":"2573667109","title":"Scinai Immunotherapeutics awarded grant from Israel Innovation Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=2573667109","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573667109?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:40","pubTimestamp":1759750852,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (SCNI) announced that it has been awarded a non-dilutive grant of approximately $246,000 from the Israel Innovation Autho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-awarded-grant-from-israel-innovation-authority-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-awarded-grant-from-israel-innovation-authority-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCNI","BK4139","BK4007"],"gpt_icon":0},{"id":"2573671131","title":"Press Release: Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671131","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671131?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:30","pubTimestamp":1759750200,"startTime":"0","endTime":"0","summary":"Grant funds two-thirds of a NIS 1.23 million  project to strengthen Scinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad. JERUSALEM, Oct. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company with a growing boutique contract development and manufacturing organization  business unit, Scinai Bioservices, today announced that it has been awarded a non-dilutive grant of approximately NIS 809,000  from the Israel Innovation Authority . The grant will fund approximately 66% of a NIS 1.23 million  project aimed at acquiring and installing an advanced fill-and-finish system for sterile manufacturing. This investment addresses a major industry gap, as most early-stage biotech companies in Israel lack access to local, flexible, small-scale GMP manufacturing. As a result, many are forced to outsource overseas at high cost, with long lead times and limited control. Designed ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","CDMO","BK4007","SCNI","TEN","BK4139","BK4144"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scinai.com","stockEarnings":[{"period":"1week","weight":-0.0551},{"period":"1month","weight":-0.0596},{"period":"3month","weight":-0.1666},{"period":"6month","weight":-0.5611},{"period":"1year","weight":-0.7907},{"period":"ytd","weight":-0.017}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.123027},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.04681},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.032392},{"month":4,"riseRate":0.5,"avgChangeRate":0.075096},{"month":5,"riseRate":0.5,"avgChangeRate":0.025358},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.041702},{"month":7,"riseRate":0.545455,"avgChangeRate":0.067743},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.046786},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.108328},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.094214},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.010725},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.063466}],"exchange":"NASDAQ","name":"Scinai Immunotherapeutics Ltd.","nameEN":"Scinai Immunotherapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Scinai Immunotherapeutics Ltd.(SCNI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Scinai Immunotherapeutics Ltd.(SCNI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Scinai Immunotherapeutics Ltd.,SCNI,Scinai Immunotherapeutics Ltd.股票,Scinai Immunotherapeutics Ltd.股票老虎,Scinai Immunotherapeutics Ltd.股票老虎国际,Scinai Immunotherapeutics Ltd.行情,Scinai Immunotherapeutics Ltd.股票行情,Scinai Immunotherapeutics Ltd.股价,Scinai Immunotherapeutics Ltd.股市,Scinai Immunotherapeutics Ltd.股票价格,Scinai Immunotherapeutics Ltd.股票交易,Scinai Immunotherapeutics Ltd.股票购买,Scinai Immunotherapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Scinai Immunotherapeutics Ltd.(SCNI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Scinai Immunotherapeutics Ltd.(SCNI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction